Funding for this research was provided by:
National Center for Advancing Translational Sciences (#UL1TR001866 (through Rockefeller University))
Article History
Accepted: 7 June 2021
First Online: 22 June 2021
Declarations
:
: Yael Renert-Yuval, James G. Krueger, and Jonathan N. Tobin were supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award program through The Rockefeller University, Grant no. UL1TR001866.
: James G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. Jonathan N. Tobin has received research support (grants paid to his institution) and/or personal fees from National Institutes of Health, Agency for Healthcare Research and Quality, Patient-Centered Outcomes Research Institute, Bio-Ascend LLC, Regional Cancer Care Associates, Washington University in St. Louis, Astra Zeneca, Merck, Bristol Myers Squibb, Purdue Pharma, and Syneos. Yael Renert-Yuval has no conflicts of interest that are directly relevant to the content of this letter.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.